<DOC>
	<DOCNO>NCT03053115</DOCNO>
	<brief_summary>The aim study evaluate peripheral tissue response combine administration levothyroxine ( LT4 ) liothyronine ( LT3 ) hypothyroid patient residual thyroid function virtually absent ( thyroidectomized ) . Cases treat LT4+LT3 , personalize dos accord clinical guideline respect circadian rhythmicity LT3 physiological T3/T4 ratio . Controls treat LT4 placebo . Treatment duration : 24 week . The primary endpoint peripheral effect thyroid hormone , measure tissue marker level , thyroid stimulate hormone ( TSH ) , sex hormone bind globulin ( SHBG ) , total cholesterol , LDL cholesterol , lipoprotein A , osteocalcin , urinary N-telopeptide , ferritin , myoglobin , creatine kinase , glucose 6 phosphate dehydrogenases , angiotensin-converting enzyme ( ACE ) . The secondary endpoint bone metabolic modification , evaluate DEXA , quality life , tissue specific miRNA expression , polymorphisms gene involve thyroid hormone metabolism .</brief_summary>
	<brief_title>Combined Replacement Therapy With Levothyroxine Liothyronine Thyroidectomized Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypothyroidism</mesh_term>
	<criteria>old 18 year capable consent able fill questionnaire italian thyroidectomized serum thyroglobulin level 0.2 ng/ml antibody antithyroglobulin undetectable ( normal range ) well treat take stable dos levothyroxine tablet , previous 3 month TSH suppressive therapy pregnancy cardiac arrhythmia severe liver , kidney bone disease ongoing steroid treatment ongoing previous 12 month treatment bone antiresorptive , amiodarone , colestyramine iron .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>